Danapha Pharmaceutical JSC

    Danapha Pharmaceutical JSC

    UUPCOM:DAN
    25,000.00
    VND
    +2,200.00
    (+9.65%)
    Danapha Pharmaceutical JSC
    UPCOM:DAN
    (Unlisted Public Company Market)

    Recent

    price

    25,000.00

    P/E

    ratio

    - -

    div

    yld

    - -

    ROIC.AI

    No data availableFinancial data will appear here once available

    Capital Structure

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Working Capital

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Growth Rates

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Quarterly Revenue

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Quarterly Earnings Per Share

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Quarterly Dividends Per Share

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available
    Similar Companies
    Business
    Danapha Pharmaceutical Joint Stock Company is a Vietnam-based pharmaceutical manufacturing and healthcare enterprise engaged in the research, development, production, and distribution of chemical pharmaceuticals, herbal medicines, and consumer healthcare products. Founded in 1965 as the Central Drug Workshop and equitized into a joint-stock company in 2007, the company is headquartered in Da Nang, Vietnam, and trades on the Unlisted Public Company Market under the ticker UPCOM:DAN, with Danhson VN Company Ltd and state-owned entities representing major shareholding interests. Danapha develops and manufactures an extensive portfolio of more than 200 commercial products across solid, semi-solid, liquid, and sterile dosage forms, including cardiovascular and diabetes medications; analgesics, anti-inflammatories, and arthritis treatments; respiratory, antihistamine, and cough preparations; central nervous system therapies, antipsychotics, and nootropics; gastrointestinal and digestive remedies; ophthalmic drops, nasal sprays, and topical ointments; traditional herbal and phytotherapeutic formulations under key brands such as Tadimax for benign prostatic hyperplasia, Bai Thach for urinary stones, and Vg5 for hepatoprotection; medicated oils, inhalers, and balms under the Golden Star brand; as well as specialized nanomedicines and lipid-based formulations for oncology and complex therapeutic applications. The company supplies public hospital networks, private clinics, and retail pharmacy chains across Vietnam, while maintaining export operations in approximately 20 international markets spanning Southeast Asia and Eastern Europe, including Russia, Ukraine, Uzbekistan, and Bulgaria. In recent operational developments, Danapha advanced its high-technology manufacturing facility and research center in the Da Nang Hi-Tech Park, providing an annual production capacity of approximately 1.5 billion units. Following its receipt of European Union Good Manufacturing Practice (EU-GMP) certification for non-sterile manufacturing lines in 2022, Danapha achieved EU-GMP certification for sterile dosage forms in 2025, establishing the company as the first pharmaceutical manufacturer in Vietnam to earn EU-GMP accreditation for sterile production. Concurrently, the company continues to accelerate export commercialization across European and Eurasian markets, expand its proprietary phytosome and liposomal drug delivery platforms, and broaden its contract development and manufacturing partnerships.